Ozempic Users Win Eye-Disease Payout in Novo’s Home Market (1)

Four patients who developed a serious eye disease after using Novo Nordisk A/S’s blockbuster weight-loss drugs have been granted compensation in Denmark, the drugmaker’s home market.

The claimants received a combined 800,000 kroner ($124,000), though that figure may rise if further loss of earnings is proven, according to Danish Patient Compensation, an independent association financed by the state and insurers.

So far, the body said it has received 43 claims from patients who believe they developed the condition known as NAION after taking Wegovy or Ozempic. The agency has ruled on five cases, granting compensation in four and rejecting ...